Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, September 30, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$63.16M
Return on Equity (ROE)
-62.81%
TTM Avg
-75.79%
3Y Avg
-56.25%
5Y Avg
-48.09%
Market Cap
$63.35M
Return on Equity (ROE)
-492.89%
TTM Avg
-50.27%
3Y Avg
-279.07%
5Y Avg
-249.48%
Market Cap
$63.79M
Return on Equity (ROE)
-8.80%
TTM Avg
-13.04%
3Y Avg
-7.69%
5Y Avg
-7.21%
Market Cap
$64.20M
Return on Equity (ROE)
-136.82%
TTM Avg
-201.41%
3Y Avg
-55.55%
5Y Avg
-39.58%
Market Cap
$64.80M
Return on Equity (ROE)
N/A
TTM Avg
-26.44%
3Y Avg
-559.66%
5Y Avg
-417.87%
Market Cap
$61.06M
Return on Equity (ROE)
-76.75%
TTM Avg
-53.49%
3Y Avg
-5.79%
5Y Avg
-19.88%
Market Cap
$60.98M
Return on Equity (ROE)
N/A
TTM Avg
-866.00%
3Y Avg
-422.47%
5Y Avg
-312.54%
Market Cap
$60.49M
Return on Equity (ROE)
-30.21%
TTM Avg
-215.14%
3Y Avg
-180.32%
5Y Avg
47.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alps Group Inc (ALPS) | $63.23M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | -62.81% | -75.79% | -56.25% | -48.09% |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.35M | -492.89% | -50.27% | -279.07% | -249.48% |
| InterCure Ltd. (INCR)vs › | $63.79M | -8.80% | -13.04% | -7.69% | -7.21% |
| RenovoRx, Inc. (RNXT)vs › | $64.20M | -136.82% | -201.41% | -55.55% | -39.58% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.80M | N/A | -26.44% | -559.66% | -417.87% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.06M | -76.75% | -53.49% | -5.79% | -19.88% |
| Fractyl Health, Inc. (GUTS)vs › | $60.98M | N/A | -866.00% | -422.47% | -312.54% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | -30.21% | -215.14% | -180.32% | 47.11% |
| Cingulate Inc. (CING)vs › | $66.00M | -122.71% | -558.46% | -307.41% | -314.14% |
ROE
N/A
ROA
-39.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-09-30 | -3.07% |
